F182112

F182112 is a bispecific antibody that targets both B-cell maturation antigen (BCMA) and CD3. It functions by redirecting CD3+ T cells to mediate T-cell activation and subsequent lysis of BCMA-expressing myeloma cells. This mechanism enables the immune system to specifically target and destroy malignant plasma cells in multiple myeloma. F182112 is being developed as an intravenous immunotherapy for patients with relapsed or refractory multiple myeloma who have received at least two prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The drug is currently undergoing phase 1 clinical trials to evaluate its safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy[1][2][4][8]. The development is sponsored by Shandong New Time Pharmaceutical Co. Ltd., with Lunan Pharmaceutical Group Co., Ltd. as the originator[1][3].